The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis

K Riazi, H Azhari, JH Charette… - The lancet …, 2022 - thelancet.com
Background Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease
worldwide and the leading cause of liver-related morbidity and mortality. We aimed to …

American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and …

K Cusi, S Isaacs, D Barb, R Basu, S Caprio… - Endocrine Practice, 2022 - Elsevier
Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease

ME Rinella, BA Neuschwander-Tetri, MS Siddiqui… - Hepatology, 2023 - journals.lww.com
Abbreviations: AASLD, American Association for the Study of Liver Diseases; AI, artificial
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …

A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis

SA Harrison, P Bedossa, CD Guy… - … England Journal of …, 2024 - Mass Medical Soc
Background Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no
approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta …

Challenges and opportunities in NASH drug development

SA Harrison, AM Allen, J Dubourg, M Noureddin… - Nature medicine, 2023 - nature.com
Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic
steatohepatitis (NASH), represent a growing worldwide epidemic and a high unmet medical …

Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta …

J Quek, KE Chan, ZY Wong, C Tan, B Tan… - The lancet …, 2023 - thelancet.com
Background The global burden of non-alcoholic fatty liver disease (NAFLD) parallels the
increase in obesity rates across the world. Although overweight and obesity status are …

Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial

SA Harrison, R Taub, GW Neff, KJ Lucas, D Labriola… - Nature medicine, 2023 - nature.com
Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved
treatment. MAESTRO-NAFLD-1 was a 52-week randomized, double-blind, placebo …

A global view of the interplay between non-alcoholic fatty liver disease and diabetes

N Stefan, K Cusi - The lancet Diabetes & endocrinology, 2022 - thelancet.com
Non-alcoholic fatty liver disease (NAFLD) has become an epidemic, much like other non-
communicable diseases (NCDs), such as cancer, obesity, diabetes, and cardiovascular …

Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association

PB Duell, FK Welty, M Miller, A Chait… - … , and vascular biology, 2022 - Am Heart Assoc
Nonalcoholic fatty liver disease (NAFLD) is an increasingly common condition that is
believed to affect> 25% of adults worldwide. Unless specific testing is done to identify …

[HTML][HTML] 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Care in Diabetes—2023

NA ElSayed, G Aleppo, VR Aroda, RR Bannuru… - Diabetes …, 2023 - ncbi.nlm.nih.gov
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …